Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi‐stakeholder, international workshop
Open Access
- 3 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Health Services Research
- Vol. 21 (1), 1-9
- https://doi.org/10.1186/s12913-021-06425-0
Abstract
It is increasingly common for two or more treatments for cancer to be combined as a single regimen. Determining value and appropriate payment for such regimens can be challenging. This study discusses these challenges, and possible solutions. Stakeholders from around the world attended a 2-day workshop, supported by a background paper. This study captures key outcomes from the discussion, but is not a consensus statement. Workshop attendees agreed that combining on-patent treatments can result in affordability and value for money challenges that delay or deny patient access to clinically effective treatments in many health systems. Options for addressing these challenges include: (i) Increasing the value of combination therapies through improved clinical development; (ii) Willingness to pay more for combinations than for single drugs offering similar benefit, or; (iii) Aligning the cost of constituent therapies with their value within a regimen. Workshop attendees felt that (i) and (iii) merited further discussion, whereas (ii) was unlikely to be justifiable. Views differed on the feasibility of (i). Key to (iii) would be systems allowing different prices to apply to different uses of a drug. Common ground was identified on immediate actions to improve access to combination regimens. These include an exploration of the legal challenges associated with price negotiations, and ensuring that pricing systems can support implementation of negotiated prices for specific uses. Improvements to clinical development and trial design should be pursued in the medium and longer term.Keywords
Funding Information
- Bellberry Limited (Bellberry Limited, Bellberry Limited, Bellberry Limited, Bellberry Limited)
- Yorkshire Cancer Research (S406NL)
This publication has 12 references indexed in Scilit:
- Not cost-effective at zero price: valuing and paying for combination therapies in cancerExpert Review of Pharmacoeconomics & Outcomes Research, 2021
- Challenges in the value assessment, pricing and funding of targeted combination therapies in oncologyHealth Policy, 2019
- This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocolsTrials, 2019
- Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisonsTrials, 2019
- Drug repurposing: progress, challenges and recommendationsNature Reviews Drug Discovery, 2018
- Adaptive designs in clinical trials: why use them, and how to run and report themBMC Medicine, 2018
- Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New InnovationsApplied Health Economics and Health Policy, 2018
- Multi-Indication Pricing: Pros, Cons, And Its Applicability To The United KingdomValue in Health, 2016
- Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast CancerPharmacoEconomics, 2014
- Opportunities and Challenges in the Development of Experimental Drug Combinations for CancerJNCI Journal of the National Cancer Institute, 2011